{
  "pmcid": "6389380",
  "sha256": "fd3a0050444bae68be01b2f1a2407a5eee7d593e73acba2ae739e81cbff33fff",
  "timestamp_utc": "2025-11-09T16:08:38.714211+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.763600000000004,
    "reading_ease": 30.636569230769226,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The CIT-01 study was a phase II, multicenter, open label, active control, randomized study."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Twenty-four subjects were randomized to peritransplant intraportal and systemic treatment with either LMW-DS or heparin."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Twenty-four subjects were randomized to peritransplant intraportal and systemic treatment with either LMW-DS or heparin."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "C-peptide response was measured with a mixed meal tolerance test at 75 and 365 days after transplant."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 1,
        "evidence": "open label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Twenty-four subjects were randomized"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "There was no difference in the primary endpoint (stimulated C-peptide 75±5 days after the first transplant) between the 2 arms (1.33±1.10 versus 1.56±1.36 ng/mL, p=0.66)."
      },
      "Harms": {
        "score": 1,
        "evidence": "LMW-DS was safe and well tolerated with similar observed adverse events (mostly attributed to immunosuppression) as in the heparin arm."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  }
}